^
    Back
    Association details:
    Biomarker:B2M mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Eur J Haematol
    Title:

    Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients

    Published date:
    06/09/2023
    Excerpt:
    In this single-center, single-arm phase 2 and retrospective study, r/r DLBCL patients received PD-1 mab and Rituximab every 3 weeks….B2M mutations correlated with a significantly poor PFS (p = .013) and OS (p = .009) in DLBCL patients treated with this regimen.
    DOI:
    https://doi.org/10.1111/ejh.14013